Na Eprel 17, 2025, Hansoh Pharmaceutical kwupụtara na ọgwụ B7-H3 nke otu ahụ mepụtara n'onwe ya maka ọgwụ mgbochi-ọgwụ (ADC) HS-20093 maka ịgba ọgwụ enwetala nkwenye ka etinye ya dị ka ọgwụ Breakthrough-Therapy-Designated site na National Medical Products Administration (NMPA) nke China, yana ihe atụ a tụrụ aro maka kansa akpa ume nke dị n'ógbè ma ọ bụ nke na-abụghị obere mkpụrụ ndụ (NSCLC) nke na-enweghị mgbanwe ndị ọkwọ ụgbọala, nke gara n'ihu ma ọ bụ na-emegharị mgbe ọgwụgwọ dabere na platinum gasịrị.
HS-20093 bụ ADC nke e ji nyocha B7-H3 mee, nke nwere ihe mgbochi mmadụ nke na-egbochi B7-H3 monoclonal zuru oke nke jikọtara ya na ibu ọrụ topoisomerase inhibitor (TOPOi) ma na-emepụta ya maka ọgwụgwọ nke kansa akpa ume, sarcoma, kansa isi na olu na etuto ndị ọzọ siri ike na ọtụtụ nnwale ahụike na China, ebe nyocha kachasị elu bụ nnwale ahụike nke Phase Ⅲ.
A na-akwado nhazi a site na data ahụike mbụ sitere na ọmụmụ ARTEMIS-001. Nke a bụ nnwale nke ngalaba nke mbụ na-emeghe, nke nwere ọtụtụ ebe nyocha nke ihe karịrị ndị ọrịa 300 na-enyocha nchekwa, nnabata, na ọrụ mgbochi etuto ahụ na etuto siri ike dị elu ma ọ bụ nke metastatic (ọrịa kansa akpa ume nke dị elu ma ọ bụ nke na-abụghị nke squamous nke na-abụghị obere sel na-enweghị mgbanwe ọkwọ ụgbọala, na-aga n'ihu ma ọ bụ na-emegharị mgbe ọgwụgwọ chemotherapy dabere na platinum) nke Hansoh Pharma mere.
Na mbụ, HS-20093 enwetala nkwenye ka a tinye ya dị ka ọgwụ a họpụtara maka ọgwụgwọ ọhụrụ site n'aka NMPA maka ihe ngosi abụọ:
· Kansa Nkuume Obere-Mkpụrụ Ndụ (ES-SCLC) nke a malitere mgbe ọgwụgwọ mbụ gasịrị (ọgwụgwọ platinum doublet chemotherapy jikọtara ya na ọgwụ mgbochi).
· Ọkpụkpụ ọkpụkpụ (osteosarcoma) na ndị ọrịa nwere ọganihu na opekata mpe usoro ọgwụgwọ abụọ gara aga.
Ugbu a, enwere ọtụtụ nnwale ahụike nke teknụzụ ọhụrụ na-egbochi kansa na China na-achọ ndị ọrịa. Maka ndụmọdụ gbasara ọgwụ na teknụzụ ọhụrụ, ị nwere ike ịkpọtụrụ Ngalaba Mba Nile nke Ụlọ Ọgwụ Oncology nke Beijing South Region.
Nọmba ekwentị: 4008803716
Email：myimmnet@163.com
Oge ozi: Eprel-22-2025